StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Neurocrine Bio. (NBIX) PT Lowered to $104 at Needham & Company
December 12, 2018 10:48 AM
Needham & Company analyst Alan Carr lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $104.00 (from $125.00) while ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Neurocrine Bio. (NBIX) PT Lowered to $102 at H.C. Wainwright
December 13, 2018 11:09 AM
Neurocrine Bio. (NBIX) PT Lowered to $105 at Oppenheimer
December 13, 2018 9:30 AM
Neurocrine Bio. (NBIX) PT Lowered to $96 at Baird, Removed from 'Fresh Pick' List
December 12, 2018 12:16 PM
Neurocrine Biosciences (NBIX) to Resume Trading at 8 am ET
December 12, 2018 7:34 AM
Neurocrine Biosciences (NBIX) Says Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
December 12, 2018 7:31 AM
Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
December 12, 2018 7:30 AM
